Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overall (regardless of smoking Hx) Prior or current smoking Hx

Publish琅蓉 吕 Modified over 7 years ago

Similar presentations

Presentation on theme: "Overall (regardless of smoking Hx) Prior or current smoking Hx"— Presentation transcript:

1 Overall (regardless of smoking Hx) Prior or current smoking Hx
NGS or Sanger sequencing Overall (regardless of smoking Hx) Nonsmoking Hx Prior or current smoking Hx Biomarker Positive Total Percent ABL1 1 175 0.6 12 0.0 8 AKT1 185 0.5 ALK 186 APC 4.3 8.3 12.5 ATM 5 182 2.7 BRAF 3 274 1.1 13 CDH1 4 2.2 KIT (cKIT) 235 0.4 10 MET (cMET) 6 3.2 CSF1R CTNNB1 2 EGFR 193 1.6 ERBB2 ERBB4 FRXW7 FGFR1 FGFR2 FLT3 GNA11 161 7 GNAQ 115 GNAS HNF1A 159 11 HRAS 157 IDH1 JAK2 JAK3 KDR KRAS 292 4.5 MLH1 MPL NOTCH1 184 NPM1 NRAS 227 PDGFRA 181 PIK3CA 56 261 21.5 14 42.9 9 11.1 PTEN 179 3.4 PTPN11 RB1 RET SMAD4 SMARCB1 SMO 166 STK11 TP53 97 52.7 50.0 62.5 VHL 174 Supplementary table 2: Sanger or NGS data for bladder cancer patients

Download ppt "Overall (regardless of smoking Hx) Prior or current smoking Hx"

Similar presentations

FOUNDER, SCIENTIFIC DIRECTOR

FOUNDER, SCIENTIFIC DIRECTOR
Oncogenic Mutation Screening in Solitary Fibrous Tumors Elizabeth G. Demicco, Khalida Wani, Kenneth Aldape, Alexander J. Lazar, and Wei-Lien Wang.

Oncogenic Mutation Screening in Solitary Fibrous Tumors Elizabeth G. Demicco, Khalida Wani, Kenneth Aldape, Alexander J. Lazar, and Wei-Lien Wang.
Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.

Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.
RECURRENT CHROMOSOMAL COPY NUMBER ALTERATIONS IN CHORDOMA G. Petur Nielsen; John Iafrate; Zhenfeng Duan; Ramnik Xavier; Joseph Schwab; Andrew Rosenberg;

RECURRENT CHROMOSOMAL COPY NUMBER ALTERATIONS IN CHORDOMA G. Petur Nielsen; John Iafrate; Zhenfeng Duan; Ramnik Xavier; Joseph Schwab; Andrew Rosenberg;
Molecular Testing of lung cancer in routine practice

Molecular Testing of lung cancer in routine practice
KRAS testing in colorectal cancer

KRAS testing in colorectal cancer
The Many Faces of Personalized Health Care: Pediatric and Medical Oncology Joshua D. Schiffman, MD Edward B. Clark, MD Chair in Pediatric Research Associate.

The Many Faces of Personalized Health Care: Pediatric and Medical Oncology Joshua D. Schiffman, MD Edward B. Clark, MD Chair in Pediatric Research Associate.
1 Research Data Marts In Support Of Cancer Personalized Medicine Jack London, PhD and Devjani Chatterjee, PhD Jefferson Kimmel Cancer Center, Philadelphia.

1 Research Data Marts In Support Of Cancer Personalized Medicine Jack London, PhD and Devjani Chatterjee, PhD Jefferson Kimmel Cancer Center, Philadelphia.
1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.

1 Jack London, PhD Research Professor, Cancer Biology Thomas Jefferson University Informatics Shared Resource Director Sidney Kimmel Cancer Center at Jefferson.
Exome sequencing analysis of the mutational spectrum in carcinogen and genetic models of Kras-driven lung cancer Peter Westcott, Kyle Halliwill, Minh To,

Exome sequencing analysis of the mutational spectrum in carcinogen and genetic models of Kras-driven lung cancer Peter Westcott, Kyle Halliwill, Minh To,
Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.

Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.
Supplementary Fig. S1 A.B.. A. Supplementary Fig. S2 B. C.

Supplementary Fig. S1 A.B.. A. Supplementary Fig. S2 B. C.
HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.

HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131)

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131)
A novel 3D human tissue culture model

A novel 3D human tissue culture model
Evaristo Maiello U.O.C. Oncologia IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo (FG) Napoli, 16 ottobre 2015.

Evaristo Maiello U.O.C. Oncologia IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo (FG) Napoli, 16 ottobre 2015.
Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.
Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello

Module 4: How do unrealistic expectations confound the results of our analyses Case Studies in Bioinformatics Giovanni Ciriello
Evidence-guided tumor profiling to individualize therapy decisions.

Evidence-guided tumor profiling to individualize therapy decisions.
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) A phase II precision medicine cancer trial Co-developed by the ECOG-ACRIN Cancer Research.

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) A phase II precision medicine cancer trial Co-developed by the ECOG-ACRIN Cancer Research.

Similar presentations

Ads by Google